Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - POZEN INC /NCexhibit99_1.htm


UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C. 20549
 
_______________________________
 
FORM 8-K
 
CURRENT REPORT
 
PURSUANT TO SECTION 13 OR 15(d) OF THE
 
SECURITIES EXCHANGE ACT OF 1934
 

 
Date of report (Date of earliest event reported): December 16, 2014
 
POZEN INC.
 
(Exact Name of Registrant as Specified in Charter)

Delaware
000-31719
62-1657552
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)

1414 Raleigh Road, Suite 400
Chapel Hill, North Carolina
27517
(Address of Principal Executive Offices)
(Zip Code)

(919) 913-1030
(Registrant's telephone number, including area code)

Not applicable
(Former Name or Former Address, if Changed Since Last Report)

 
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

 
 

 


Item 8.01.
Other Events.
 

 
On December 17, 2014, POZEN Inc., a Delaware corporation (“POZEN”), issued a press release to report the U.S. Food and Drug Administration’s (FDA) action regarding POZEN’s new drug application (NDA) for PA8140/PA32540. The full text of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.
 

 
Item 9.01.
Financial Statements and Exhibits.
 
(c) Exhibits.
 
Exhibit No.
 
Description
99.1
 
Press Release of POZEN Inc. dated December 17, 2014

 

 
 

 


 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
POZEN Inc.
     
 
By:
/s/ William L. Hodges
 
Name:
William L. Hodges
 
Title:
Chief Financial Officer

 
Date:  December 17, 2014